Zobrazeno 1 - 10
of 688
pro vyhledávání: '"Gregory J, Riely"'
Autor:
Richard A. Hickman, Alexandra M. Miller, Bridget M. Holle, Justin Jee, Si-Yang Liu, Dara Ross, Helena Yu, Gregory J. Riely, Christina Ombres, Alexandra N. Gewirtz, Anne S. Reiner, Subhiksha Nandakumar, Adam Price, Thomas J. Kaley, Maya S. Graham, Chad Vanderbilt, Satshil Rana, Katherine Hill, Kiana Chabot, Carl Campos, Khedoudja Nafa, Neerav Shukla, Matthias Karajannis, Bob Li, Michael Berger, Marc Ladanyi, Elena Pentsova, Adrienne Boire, A. Rose Brannon, Tejus Bale, Ingo K. Mellinghoff, Maria E. Arcila
Publikováno v:
Acta Neuropathologica Communications, Vol 12, Iss 1, Pp 1-13 (2024)
Abstract The characterization of genetic alterations in tumor samples has become standard practice for many human cancers to achieve more precise disease classification and guide the selection of targeted therapies. Cerebrospinal fluid (CSF) can serv
Externí odkaz:
https://doaj.org/article/d891582bd5b340c8aff11cbf672c3107
Autor:
Brandon S. Imber, MD, MA, Ryka Sehgal, MD, Rachel Saganty, MD, Anne S. Reiner, MPH, A. Turan Ilica, MD, Emily Miao, PharmD, Bob T. Li, MD, Gregory J. Riely, MD, Helena A. Yu, MD, Katherine S. Panageas, DrPH, Robert J. Young, MD, Luke R.G. Pike, MD, DPhil, Nelson S. Moss, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100607- (2023)
Introduction: Patients with EGFR-mutant NSCLC have a high incidence of brain metastases. The EGFR-directed tyrosine kinase inhibitor osimertinib has intracranial activity, making the role of local central nervous system (CNS)-directed therapies, such
Externí odkaz:
https://doaj.org/article/eb50687c81bc4fa09768c4beb4a3d785
Autor:
Rohit Thummalapalli, MD, Noura J. Choudhury, MD, Fiona Ehrich, MS, Tyler Beardslee, PharmD, Danielle Brazel, MD, Shannon S. Zhang, MD, Shelby Merchant, PharmD, Monica F. Chen, MD, Glenn Heller, PhD, Suresh S. Ramalingam, MD, Sai-Hong Ignatius Ou, MD, PhD, Kathryn F. Mileham, MD, Gregory J. Riely, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 8, Pp 100546- (2023)
Introduction: Treatment with lorlatinib for patients with advanced ALK- and ROS1-rearranged NSCLC (ALK+ and ROS1+ NSCLC) is associated with a unique set of adverse events (AEs) often requiring dose reduction. However, the impact of dose reductions on
Externí odkaz:
https://doaj.org/article/4a17b716e5554aaa9e42589db4af6e82
Autor:
Melissa Y.Y. Moey, Cassandra Hennessy, Benjamin French, Jeremy L. Warner, Matthew D. Tucker, Daniel J. Hausrath, Dimpy P. Shah, Jeanne M. DeCara, Ziad Bakouny, Chris Labaki, Toni K. Choueiri, Susan Dent, Nausheen Akhter, Roohi Ismail-Khan, Lisa Tachiki, David Slosky, Tamar S. Polonsky, Joy A. Awosika, Audrey Crago, Trisha Wise-Draper, Nino Balanchivadze, Clara Hwang, Leslie A. Fecher, Cyndi Gonzalez Gomez, Brandon Hayes-Lattin, Michael J. Glover, Sumit A. Shah, Dharmesh Gopalakrishnan, Elizabeth A. Griffiths, Daniel H. Kwon, Vadim S. Koshkin, Sana Mahmood, Babar Bashir, Taylor Nonato, Pedram Razavi, Rana R. McKay, Gayathri Nagaraj, Eric Oligino, Matthew Puc, Polina Tregubenko, Elizabeth M. Wulff-Burchfield, Zhuoer Xie, Thorvardur R. Halfdanarson, Dimitrios Farmakiotis, Elizabeth J. Klein, Elizabeth V. Robilotti, Gregory J. Riely, Jean-Bernard Durand, Salim S. Hayek, Lavanya Kondapalli, Stephanie Berg, Timothy E. O'Connor, Mehmet A. Bilen, Cecilia Castellano, Melissa K. Accordino, Blau Sibel, Lisa B. Weissmann, Chinmay Jani, Daniel B. Flora, Lawrence Rudski, Miriam Santos Dutra, Bouganim Nathaniel, Erika Ruíz-García, Diana Vilar-Compte, Shilpa Gupta, Alicia Morgans, Anju Nohria
Publikováno v:
Translational Oncology, Vol 34, Iss , Pp 101709- (2023)
Background: Data regarding outcomes among patients with cancer and co-morbid cardiovascular disease (CVD)/cardiovascular risk factors (CVRF) after SARS-CoV-2 infection are limited. Objectives: To compare Coronavirus disease 2019 (COVID-19) related co
Externí odkaz:
https://doaj.org/article/9d648aa2b95644a1af71f1806e404101
Autor:
Yuan Chen, Biagio Ricciuti, Matthew D Hellmann, Hira Rizvi, Mark M Awad, Giuseppe Lamberti, Arielle Elkrief, Jamie E Chaft, Xinan Wang, Samantha Brown, Charles M Rudin, Joao M Victor Alessi, Isabel R Preeshagul, Federica Pecci, Alessandro Di Federico, Jacklynn V Egger, Gregory J Riely, Mark G Kris, Marc Ladanyi, Ronglai Shen, Adam J Schoenfeld
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 7 (2023)
Background Single-agent PD-(L)1 blockade (IO) alone or in combination with chemotherapy (Chemotherapy-IO) is approved first-line therapies in patients with advanced lung adenocarcinomas (LUADs) with PD-L1 expression ≥1%. These regimens have not bee
Externí odkaz:
https://doaj.org/article/1db67c48820e42a9b021621d9022be62
Autor:
Dong-Wan Kim, MD, PhD, Shirish Gadgeel, MD, Scott N. Gettinger, MD, Gregory J. Riely, MD, PhD, Geoffrey R. Oxnard, MD, Tarek Mekhail, MD, Peter Schmid, MD, PhD, Afshin Dowlati, MD, Rebecca S. Heist, MD, MPH, Antoinette J. Wozniak, MD, Jatinder Singh, PhD, Edward Cha, MD, PhD, Jessica Spahn, PhD, Sai-Hong Ignatius Ou, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 8, Pp 100367- (2022)
Introduction: Alectinib is a preferred first-line treatment option for advanced ALK-positive NSCLC. Combination regimens of alectinib with immune checkpoint inhibitors are being evaluated for synergistic effects. Methods: Adults with treatment-naive,
Externí odkaz:
https://doaj.org/article/ef3f254cb8784bd19307c98d578cc81c
Autor:
Maria M. Rubinstein, Cheryl Goss, Scott T. Avecilla, Gregory P. Dubé, Gregory J. Riely, Jodi V. Mones
Publikováno v:
Clinical Case Reports, Vol 8, Iss 2, Pp 289-292 (2020)
Abstract Pure red cell aplasia (PRCA) is a rare paraneoplastic syndrome occasionally associated with thymomas. Here, we report on the first ever use of a bovine hemoglobin‐based oxygen carrier, HBOC‐201 (HbO2 Therapeutics LLC; Hemopure®, Waltham
Externí odkaz:
https://doaj.org/article/c3cd86fc5e4947e7bc74104957d89e2a
Autor:
Kathryn C. Arbour, MD, Eusebio Manchado, PhD, Matthew J. Bott, MD, Linda Ahn, NP, Yosef Tobi, BA, Andy Ai Ni, Helena A. Yu, MD, Alyssa Shannon, BA, Marc Ladanyi, MD, Victoria Perron, BS, Michelle S. Ginsberg, MD, Amanda Johnson, BA, Andrei Holodny, MD, Mark G. Kris, MD, Charles M. Rudin, MD, PhD, Piro Lito, MD, PhD, Neal Rosen, MD, PhD, Scott Lowe, PhD, Gregory J. Riely, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 1, Pp 100256- (2022)
Introduction: Somatic KRAS mutations occur in 25% of patients with NSCLC. Treatment with MEK inhibitor monotherapy has not been successful in clinical trials to date. Compensatory activation of FGFR1 was identified as a mechanism of trametinib resist
Externí odkaz:
https://doaj.org/article/08ab67b4ab914fc8921cb36a60feebfe
Autor:
Ziad, Bakouny, Chris, Labaki, Punita, Grover, Joy, Awosika, Shuchi, Gulati, Chih-Yuan, Hsu, Saif I, Alimohamed, Babar, Bashir, Stephanie, Berg, Mehmet A, Bilen, Daniel, Bowles, Cecilia, Castellano, Aakash, Desai, Arielle, Elkrief, Omar E, Eton, Leslie A, Fecher, Daniel, Flora, Matthew D, Galsky, Margaret E, Gatti-Mays, Alicia, Gesenhues, Michael J, Glover, Dharmesh, Gopalakrishnan, Shilpa, Gupta, Thorvardur R, Halfdanarson, Brandon, Hayes-Lattin, Mohamed, Hendawi, Emily, Hsu, Clara, Hwang, Roman, Jandarov, Chinmay, Jani, Douglas B, Johnson, Monika, Joshi, Hina, Khan, Shaheer A, Khan, Natalie, Knox, Vadim S, Koshkin, Amit A, Kulkarni, Daniel H, Kwon, Sara, Matar, Rana R, McKay, Sanjay, Mishra, Feras A, Moria, Amanda, Nizam, Nora L, Nock, Taylor K, Nonato, Justin, Panasci, Lauren, Pomerantz, Andrew J, Portuguese, Destie, Provenzano, Matthew, Puc, Yuan J, Rao, Terence D, Rhodes, Gregory J, Riely, Jacob J, Ripp, Andrea V, Rivera, Erika, Ruiz-Garcia, Andrew L, Schmidt, Adam J, Schoenfeld, Gary K, Schwartz, Sumit A, Shah, Justin, Shaya, Suki, Subbiah, Lisa M, Tachiki, Matthew D, Tucker, Melissa, Valdez-Reyes, Lisa B, Weissmann, Michael T, Wotman, Elizabeth M, Wulff-Burchfield, Zhuoer, Xie, Yuanchu James, Yang, Michael A, Thompson, Dimpy P, Shah, Jeremy L, Warner, Yu, Shyr, Toni K, Choueiri, Trisha M, Wise-Draper, Catherine, Stratton
Publikováno v:
JAMA oncology.
ImportanceCytokine storm due to COVID-19 can cause high morbidity and mortality and may be more common in patients with cancer treated with immunotherapy (IO) due to immune system activation.ObjectiveTo determine the association of baseline immunosup
Autor:
David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm DeCamp, Thomas J. Dilling, Jonathan Dowell, Gregory A. Durm, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Sandip P. Patel, Tejas Patil, Patricio M. Polanco, Gregory J. Riely, Jonathan Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, Miranda Hughes
Publikováno v:
Journal of the National Comprehensive Cancer Network. 21:340-350
The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) provide recommendations for management of disease in patients with NSCLC. These NCCN Guidelines Insights focus on neoadjuvant and adjuvant (also known as perioperative) systemic therapy opt